Sarasota biotech company regains NYSE compliance

A Sarasota biotech company has regained compliance with the New York Stock Exchange’s American listing standards. Oragenics Inc. (NYSE American: OGEN) is now positioned to focus exclusively on advancing its lead clinical program, according to an Oct. 21 statement.

The clinical-stage biotech company, which is working on an intranasal treatment for concussion and mild traumatic brain injury, was alerted in April 2024 that it fell out of compliance with NYSE standards when its stockholders did not have at least $6 million equity, a requirement since the company had reported losses in its five most recent fiscal years. It had to submit a plan and come into compliance by Oct. 18, 2025, or face delisting.

Oragenics was notified Oct. 20 that it regained compliance with the $6 million stockholder equity requirement, according to the statement, which notes the below-compliance indicator will be removed from the OGEN listing.